Does the hivemind in Pluribus appreciate art? We asked its creators and cast

In a video call with Polygon, Pluribus creator Gilligan, Gordon Smith (director, writer, executive Producer), and Alison ...
Benzinga.com

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Forbes

Remote Or In-Office Work? The Future Lies In A Better Hybrid Model

Forbes contributors publish independent expert analyses and insights. We set an example for a better future via education and research. The possible shift back to entirely in-person work has sparked a ...
People

What Does 'Beez in the Trap' Mean? How the 2012 Song Became a Viral TikTok Trend

Everyone from Sabrina Carpenter to the Jonas Brothers are lip-syncing to a mashup of 4 Non Blondes' "What's Up?" and Nicki Minaj's "Beez in the Trap" Rodin Eckenroth/WireImage; Joe Jonas/TikTok In ...
Benzinga.com

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...
The Motley Fool

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...